Aragon Pharmaceuticals, Inc.

Genentech, Inc.

Exelixis Patent Company LLC

Seragon Pharmaceuticals, Inc.

Jackaline Dalgard Julien

Nicholas D Smith

Celine Bonnefous

Mehmet Kahraman

Steven P Govek

Johnny Yasuo Nagasawa

Andiliy Gokching Lai

Karensa L Douglas

Raju Mohan

Michael M Morrissey

Venkataiah Bollu

Brenton Todd Flatt

Mark R Herbert

Benjamin Pratt

Brant Clayton Boren

Nadia Haq

Sarah Hudson

Richard Martin

Tie-Lin Wang

Xiao-Hui Gu

Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.

Androgen receptor modulators and uses thereof

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Estrogen receptor modulators and uses thereof

Polycyclic estrogen receptor modulators and uses thereof

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

TGR5 agonists of structural formula VIII(Q), wherein X, R, R, and Rare defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases. 

TGR5 agonists

The present invention comprises TGR5 agonists of structural formula I, wherein X, R, R, and Rare defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which TGR5 is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which TGR5 is a mediator or is implicated.

Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity

Growing community of inventors

Del Mar, CA, United States of America

Jackaline Dalgard Julien